Anemos Strategy advises at both ends of the pharmaceutical organization. We help global teams design omnichannel and AI strategies that are executable in market. We help local teams execute strategies they didn't design and were never consulted on.
Most life science consultancies pick a side. Global strategy shops sell frameworks that die in translation at the affiliate level. Local agencies solve for speed and miss the bigger commercial picture. Anemos Strategy has worked both sides of that line and builds the bridge between them.
20/80, not 80/20. Content should be roughly 20% globally built, 80% locally created. Centralized production models fail at the point of execution, not the point of design.
AI is a relevance engine, not a volume engine. The goal isn't more content. It's the right content reaching the right HCP, earning attention instead of forcing channel adoption.
Aspiration before assessment. You can't diagnose the right gaps until you know where you're actually trying to go.